The company ecently announced that the FDA granted accelerated approval for Livdelzi in combination with ursodeoxycholic acidfor the treatment of primary biliary cholangitis, the analyst tells ...
The analysis revealed that 81% of individuals treated with Livdelzi achieved a composite biochemical response.
Gilead Sciences Inc. (GILD) announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which ...
US antiviral giant Gilead Sciences on Friday unveiled two-and-a-half-year interim analysis from the ongoing Phase III ASSURE ...
The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...
Gilead shares data from its Phase 3 ASSURE study, showing 81% of PBC patients treated with Livdelzi achieved a composite ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase ...
Intercept’s US president Vivek Devaraj said the pharma company still believes in the evidence supporting the liver disease ...
The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, ...
Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...
We are very encouraged by the launch of Livdelzi for primary biliary cholangitis or PBC, which was granted accelerated approval by the FDA in August. Livdelzi is a highly differentiated option for ...
Zacks.com on MSN12d
Gilead Beats on Q3 Earnings and Sales, Raises Annual OutlookGilead Sciences, Inc. GILD reported better-than-expected third-quarter results and raised its annual earnings guidance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback